Remove 2040 Remove Clinical Trials Remove Concentrates
article thumbnail

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Cannabis Law Report

” The patent provides protection through 2040 and describes use of the Company’s investigational drug ANEB-001 to treat acute cannabinoid overdose. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. In October the Company announced the issuance of U.S. and Arjun Chanmugam, M.D.,